Sign In
Buy AZN
$176.43
+1.50 (+0.86%)
At Close: Jun 22, 2026
Caldwell Trust Co Purchases 10,673 Shares of Astrazeneca Plc $AZN
02:45pm, Wednesday, 29'th Apr 2026
Caldwell Trust Co increased its stake in shares of Astrazeneca Plc (NYSE: AZN) by 3,075.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission
AstraZeneca: Q1 Earnings Analysis: An Excellent Long-Term Buy And Hold
10:56am, Wednesday, 29'th Apr 2026
AstraZeneca delivered robust Q1 2026 results, with revenues up 8% year-on-year and operating profit rising 17%. AZN's oncology division remains a powerhouse, driving ~45% of revenues, with six blockbu
Astrazeneca (AZN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
10:30am, Wednesday, 29'th Apr 2026
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Stre
AstraZeneca to make $405 million investment in Britain, PM Starmer says
07:26am, Wednesday, 29'th Apr 2026
Prime Minister Keir Starmer said on Wednesday that Britain's biggest company AstraZeneca would invest 300 million pounds ($405 million) in the country, after pausing large-scale p
AstraZeneca results: Q1 2026
07:00am, Wednesday, 29'th Apr 2026
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca: Revenue and EPS summary Q1 2026 % Change $m Actual CER1 - Product Sales 14,386 12 7 - Alliance Revenue 825 29 26 Product Revenue 15,211 13 8 Col
AstraZeneca sticks to its guns after strong first-quarter revenue growth
03:05am, Wednesday, 29'th Apr 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, has reconfirmed its full-year 2026 guidance after reporting first-quarter total revenue of $15.3 billion, up 8% at constant e
AstraZeneca Gets Revenue Boost From Cancer Drugs
02:27am, Wednesday, 29'th Apr 2026
AstraZeneca reported rises in revenue and core earnings for the first quarter, saying growing sales of its cancer and rare-disease drugs lifted results.
AstraZeneca beats profit expectations, keeps annual outlook unchanged
02:05am, Wednesday, 29'th Apr 2026
AstraZeneca beat first-quarter sales and profit expectations and maintained its 2026 outlook on Wednesday, as demand for its cancer drugs and investments in the U.S. and Chi
Buy, Sell or Hold MRK Stock With Q1 Earnings Around the Corner?
11:02am, Monday, 27'th Apr 2026
Merck MRK is set to report its first-quarter 2026 earnings on April 30, before market open. The Zacks Consensus Estimate for first-quarter top line is pegged at $15.90 billion, while the same for th
Citi sees Daiichi supply review as immaterial for AstraZeneca
09:04am, Monday, 27'th Apr 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to...
Citi sees Daiichi supply review as immaterial for AstraZeneca
08:20am, Monday, 27'th Apr 2026
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to delay its full-year 2025 results, according to
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's SAPHNELO® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector, the SAPHNELO Pen, for the treatment of
Is Bristol Myers Squibb the Best Bargain in Big Pharma?
05:50am, Monday, 27'th Apr 2026
This pharma stock is cheap for a reason.
Calamos Wealth Management LLC Invests $2.90 Million in Astrazeneca Plc $AZN
03:59am, Saturday, 25'th Apr 2026
Calamos Wealth Management LLC bought a new position in Astrazeneca Plc (NYSE: AZN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Com
Insights Into Astrazeneca (AZN) Q1: Wall Street Projections for Key Metrics
10:15am, Friday, 24'th Apr 2026
Besides Wall Street's top-and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
